News
Xavier Bosch, winner of the Maurice Hilleman award for his contribution to the papillomavirus vaccine
Doctor and researcher Xavier Bosch has been selected this year as the winner of the the International Papillomavirus Society‘s Maurice Hilleman Award. The award, announced on 19 November, acknowledges the professional career and contribution to the development and promotion of the vaccines against this kind of virus. Bosch, principal investigator at the Bellvitge Biomedical Research Institute (IDIBELL), emeritus researcher at the Catalan Institute of […]
The first gene therapy approach for MLC leukoencephalopathy, designated as an orphan drug
The gene therapy approach designated as orphan drug has reduced the symptoms of MLC in the pre-clinical phase in model mice of the disease.
IDIBELL offers 10 projects for incoming INPhINIT fellowships
La Caixa Foundation concedes 35 fellowships for early-stage researchers of any nationality to pursue their PhD studies in the best Spanish and Portuguese research centres and units with excellence distinction: Spanish Seal of Excellence Severo Ochoa, María de Maeztu or Health Institute Carlos III and Portuguese units accredited as “excellent” by the Fundação de Ciência […]
AELAM donates 21.000€ to research on lymphangioleiomyomatosis
A representation from AELAM (Spanish Association of Lymphangioleiomyomatosis) delivered a donation of 21.000€ for the research on this disease. This collaboration will be used, among others, to develop a screening project for new therapeutic strategies for lymphangioleiomyomatosis (LAM). The act of delivery took place in the Duran i Reynals Hospital and counted on the attendance of the Bellvitge Institute of […]
IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects
The Spanish Association Against Cancer (AECC) distributes every year a large amount of financial aid for cancer research with the ultimate goal of bringing scientific results closer to patients, which would result in an improvement in early detection of cases and their quality of life and an increase in their survival. At IDIBELL, cancer is […]
The Innovation and Business Development Unit of IDIBELL participates in the largest congress of biotechnology industries in Europe
This is the most important event of the biotechnology, pharmaceutical, and financial industry specialized in life sciences in Europe
Sinergia 2021: the return of live science activities and release of new audiovisual content
The third edition of the L’Hospitalet health research and innovation festival will be held from 15 to 20 November, coinciding with the 26th Science Week. Live activities will take place at the Duran i Reynals Hospital and the Harmonia building in L’Hospitalet.
A new stent improves the treatment of coronary heart disease in people with diabetes
Its greater effectiveness has been verified in a study coordinated by the Bellvitge Hospital and IDIBELL. The new device reduces the number of serious complications by 35% one year after the intervention. The study was published in the world’s leading cardiovascular journal.
The study of genetic variants for the early detection of colorectal cancer: current state and future perspectives
An IDIBELL and ICO study determines that the set of genetic variants has an important role in the evolution of colorectal cancer. However, it is still too soon to use them as the single tool for screening and early detection of colorectal cancer.